OBJECTIVE: Characteristics of Canadian RA patients started on anti-tumor necrosis factor (TNF) treatment were compared with 12 other countries. METHODS: Data from the Optimization of HUMIRA trial (OH) were compared with Canadian real world studies [Ontario Biologics Research Initiative (OBRI) and the Real-Life Evaluation of Rheumatoid Arthritis in Canadians Receiving HUMIRA (REACH)], and to data from American, Australian, British, Czech, Danish, Dutch, Finnish, German, Italian, Norwegian, Spanish, and Swedish RA databases. Patient characteristics and temporal trends at initiation of anti-TNF therapy were compared between countries. RESULTS: Baseline Disease Activity Scores (DAS28) varied from 5.3 to 6.6. Lower disease severity was noted in databases from countries with less restrictive anti-TNF coverage: Dutch [based on previous disease-modifying antirheumatic drugs (DMARD) use, DAS28, swollen joint count (SJC), tender joint count (TJC), Health Assessment Questionnaire Disability Index (HAQ-DI), Danish (previous DMARD use, DAS28), Norwegian (DAS28, SJC, TJC, visual analog scale (VAS) of global health), and Swedish (DAS28, SJC, TJC, HAQ-DI)]. RA databases showed lower disease scores than did OH (P < 0.05). The US databases also showed lower disease severity (CORRONA: previous DMARD use, SJC, TJC; National Data Bank for Rheumatic Diseases: HAQ, P < 0.001). The UK and Czech Republic had restrictive coverage and higher mean baseline DAS28 than OH (P < 0.001). Baseline DAS28 in the registries with published data lowered over time (British, Norwegian, Danish, and Swedish) but less for the British (P < 0.001). CONCLUSIONS: These results confirm that regional variation exists between the 13 countries analyzed in the initiation of treatment with anti-TNF agents among RA patients and suggest that in some cases this variation may be increasing. In some countries the mean baseline disease severity declined over time and regional reimbursement policies and differences in physician preferences may be influencing initiation of anti-TNF therapy in RA.
OBJECTIVE: Characteristics of Canadian RA patients started on anti-tumor necrosis factor (TNF) treatment were compared with 12 other countries. METHODS: Data from the Optimization of HUMIRA trial (OH) were compared with Canadian real world studies [Ontario Biologics Research Initiative (OBRI) and the Real-Life Evaluation of Rheumatoid Arthritis in Canadians Receiving HUMIRA (REACH)], and to data from American, Australian, British, Czech, Danish, Dutch, Finnish, German, Italian, Norwegian, Spanish, and Swedish RA databases. Patient characteristics and temporal trends at initiation of anti-TNF therapy were compared between countries. RESULTS: Baseline Disease Activity Scores (DAS28) varied from 5.3 to 6.6. Lower disease severity was noted in databases from countries with less restrictive anti-TNF coverage: Dutch [based on previous disease-modifying antirheumatic drugs (DMARD) use, DAS28, swollen joint count (SJC), tender joint count (TJC), Health Assessment Questionnaire Disability Index (HAQ-DI), Danish (previous DMARD use, DAS28), Norwegian (DAS28, SJC, TJC, visual analog scale (VAS) of global health), and Swedish (DAS28, SJC, TJC, HAQ-DI)]. RA databases showed lower disease scores than did OH (P < 0.05). The US databases also showed lower disease severity (CORRONA: previous DMARD use, SJC, TJC; National Data Bank for Rheumatic Diseases: HAQ, P < 0.001). The UK and Czech Republic had restrictive coverage and higher mean baseline DAS28 than OH (P < 0.001). Baseline DAS28 in the registries with published data lowered over time (British, Norwegian, Danish, and Swedish) but less for the British (P < 0.001). CONCLUSIONS: These results confirm that regional variation exists between the 13 countries analyzed in the initiation of treatment with anti-TNF agents among RA patients and suggest that in some cases this variation may be increasing. In some countries the mean baseline disease severity declined over time and regional reimbursement policies and differences in physician preferences may be influencing initiation of anti-TNF therapy in RA.
Authors: Roberto Ranza; Maria Celina de la Vega; Ieda Maria Magalhães Laurindo; Marìa Gimena Gómez; David Cezar Titton; Adriana Maria Kakehasi; Alejandro Brigante; Alejandro Benitez; Aline Ranzolin; Amelia Granel; Ana María Cappuccio; Ana Quinteros; André Luiz Shinji Hayata; Andrea Smichowski; Ângela Luzia Branco P Duarte; Barbara Stadler Kahlow; Carolina Sánchez Andia; Claiton Viegas Brenol; Edson Velozo; Eduardo Mussano; Enrique R Soriano; Georges Basile Christopoulos; Geraldo da Rocha Castelar Pinheiro; Gláucio Ricardo Werner de Castro; Gustavo Casado; Hellen Mary da Silveira Carvalho; Ida Elena Exeni; Inês Guimarães da Silveira; Ingrid Petkovic; Ivanio Alves Pereira; Izaias Pereira da Costa; Javier Eduardo Rosa; José Roberto Silva Miranda; Julio Cesar Bertacini de Moraes; Manoel Barros Bertolo; Manuel Buhl; Maria Alícia Lázaro; Maria de Fátima Lobato C da Sauma; Marcelo de Medeiros Pinheiro; Monica Díaz; Mônica Valéria Siqueira Santana de Vechi; Osvaldo Luis Cerda; Pablo Astesana; Pablo Finucci Curi; Paulo Louzada-Jr; Reginaldo Botelho Teodoro; Roberto Acayaba Toledo; Sílvia Papasidero; Valeria Valim; Vander Fernandes; Veronica Saurit; Washington Alves Bianchi; Rogério de Melo Costa Pinto; Miguel Angel Descalzo; Juan Jesus Gomez-Reino Journal: Clin Rheumatol Date: 2019-04-17 Impact factor: 2.980
Authors: Gregory S Calip; Pritesh R Patel; Sruthi Adimadhyam; Shan Xing; Zhaoju Wu; Karen Sweiss; Glen T Schumock; Todd A Lee; Brian C-H Chiu Journal: Int J Cancer Date: 2018-04-16 Impact factor: 7.396
Authors: Márta Péntek; Bernadette Rojkovich; László Czirják; Pál Géher; Péter Keszthelyi; Attila Kovács; László Kovács; Zita Szabó; Zoltán Szekanecz; László Tamási; Ágnes Edit Tóth; Ilona Ujfalussy; Noémi Vártokné Hevér; Bálint Strbák; Petra Baji; Valentin Brodszky; László Gulácsi Journal: Eur J Health Econ Date: 2014-05-16